Carina Biotech: Cellular immunotherapies for the treatment of cancer
We are an Australian biotech company researching and developing chimeric antigen receptor T cell (CAR-T) therapies to treat cancer. Headquartered in Adelaide, we have a network of research providers and collaborators including leading scientists at the University of South Australia, the Women’s & Children’s Hospital, the University of Adelaide and the Seattle Children’s Hospital in the United States.
Direct investment and licensing/partnership opportunities.
Investment sought: A$5M - A$25M
No documents provided.
Project status update-
Carina Biotech is a global leader in next-generation CAR-T (chimeric antigen receptor T cell) technologies.
Expected start date
Expected end date
Funding round finish date